HC Wainwright Reiterates “Buy” Rating for Zevra Therapeutics (NASDAQ:ZVRA)

HC Wainwright reiterated their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report sent to investors on Monday morning, Benzinga reports. The brokerage currently has a $20.00 target price on the stock.

ZVRA has been the subject of several other research reports. Cantor Fitzgerald reiterated an overweight rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. JMP Securities initiated coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They set an outperform rating and a $17.00 target price for the company. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a buy rating on the stock in a report on Wednesday, September 18th. Roth Mkm upped their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a buy rating in a research report on Tuesday, September 24th. Finally, Maxim Group raised their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a buy rating in a research report on Tuesday, September 24th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics presently has an average rating of Buy and a consensus target price of $21.00.

Zevra Therapeutics Trading Up 0.3 %

Shares of ZVRA opened at $6.94 on Monday. The company has a 50-day moving average of $7.16 and a 200 day moving average of $5.75. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95. The firm has a market capitalization of $290.46 million, a price-to-earnings ratio of -5.14 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The business had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same quarter in the prior year, the firm posted ($0.15) EPS. On average, research analysts expect that Zevra Therapeutics will post -1.59 EPS for the current year.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, Director Thomas Anderson acquired 10,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was bought at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the acquisition, the director now owns 20,000 shares in the company, valued at $136,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have bought 22,000 shares of company stock worth $140,340. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Focus Financial Network Inc. ADV purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $141,000. Armistice Capital LLC purchased a new stake in shares of Zevra Therapeutics during the fourth quarter worth $1,755,000. Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at $177,000. Mystic Asset Management Inc. boosted its holdings in Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after purchasing an additional 35,514 shares during the period. Finally, Retirement Planning Co of New England Inc. grew its stake in Zevra Therapeutics by 11.0% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock worth $2,495,000 after purchasing an additional 42,766 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.